Truist Financial Corp Increases Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Truist Financial Corp boosted its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVAGet Rating) by 19.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 159,361 shares of the company’s stock after purchasing an additional 25,472 shares during the period. Truist Financial Corp’s holdings in Teva Pharmaceutical Industries were worth $1,286,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. BlackRock Inc. raised its position in shares of Teva Pharmaceutical Industries by 3.7% in the 1st quarter. BlackRock Inc. now owns 41,648,716 shares of the company’s stock valued at $391,081,000 after purchasing an additional 1,494,814 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its stake in Teva Pharmaceutical Industries by 8.1% during the 2nd quarter. Clal Insurance Enterprises Holdings Ltd now owns 18,962,766 shares of the company’s stock valued at $138,282,000 after acquiring an additional 1,424,200 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its holdings in Teva Pharmaceutical Industries by 9.3% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 11,447,527 shares of the company’s stock worth $86,085,000 after acquiring an additional 970,800 shares in the last quarter. Credit Suisse AG increased its position in shares of Teva Pharmaceutical Industries by 2.0% in the 2nd quarter. Credit Suisse AG now owns 6,894,374 shares of the company’s stock worth $51,847,000 after purchasing an additional 137,322 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Teva Pharmaceutical Industries by 13.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 6,006,352 shares of the company’s stock valued at $56,399,000 after purchasing an additional 732,558 shares in the last quarter. Institutional investors and hedge funds own 50.39% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on TEVA shares. UBS Group downgraded Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating in a research note on Friday, November 4th. BMO Capital Markets lowered their price target on Teva Pharmaceutical Industries from $11.00 to $10.00 and set a “market perform” rating for the company in a report on Monday, November 7th. JPMorgan Chase & Co. cut Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and reduced their price objective for the stock from $11.00 to $10.00 in a research note on Monday, November 14th. StockNews.com assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 12th. They set a “buy” rating for the company. Finally, Jefferies Financial Group restated a “buy” rating and issued a $10.00 price target on shares of Teva Pharmaceutical Industries in a research report on Friday, October 21st. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.44.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $10.84 on Thursday. The company has a 50-day moving average price of $9.34 and a two-hundred day moving average price of $8.95. Teva Pharmaceutical Industries Limited has a 52 week low of $6.78 and a 52 week high of $11.44. The stock has a market cap of $12.04 billion, a price-to-earnings ratio of -9.34 and a beta of 1.19. The company has a current ratio of 0.99, a quick ratio of 0.66 and a debt-to-equity ratio of 1.94.

Teva Pharmaceutical Industries (NYSE:TEVAGet Rating) last issued its quarterly earnings data on Thursday, November 3rd. The company reported $0.56 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.02). Teva Pharmaceutical Industries had a positive return on equity of 26.97% and a negative net margin of 8.52%. The business had revenue of $3.60 billion during the quarter, compared to the consensus estimate of $3.86 billion. Analysts forecast that Teva Pharmaceutical Industries Limited will post 2.4 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

(Get Rating)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

Featured Articles

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVAGet Rating).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.